HEMA - HemaCare Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
6.35
0.00 (0.00%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close6.35
Open0.00
Bid0.16 x 5000
Ask10.00 x 500
Day's Range0.00 - 0.00
52 Week Range
Volume52
Avg. Volume7,653
Market Cap65.608M
Beta1.82
PE Ratio (TTM)17.21
EPS (TTM)0.37
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire2 months ago

    HemaCare Reports Full Year 2017 Results

    HemaCare Corporation , a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy, today announced operational highlights and financial results for the year ended December 31, 2017.

  • Business Wire3 months ago

    Notice of Annual Meeting of Shareholders Before Relocating to New Expansion Facility

    HemaCare Corporation , a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, has announced that the Annual Meeting of Shareholders will be held at their corporate headquarters 15350 Sherman Way, Suite 423, Van Nuys, California on Thursday, June 7, 2018 at 8 a.m.

  • Business Wire3 months ago

    HemaCare and Charles River Laboratories Announce Strategic Partnership to Accelerate Drug Discovery and Development

    HemaCare Corporation , a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, and Charles River Laboratories International, Inc., a leading early-stage contract research organization, have formed a strategic partnership to advance human immune system research by developing a more efficient and reliable method of working with ...

  • Business Wire4 months ago

    HemaCare Announces OneBlood Exercises Second Investment Tranche Option

    HemaCare Corporation , a leading provider of human-derived primary blood cells and tissues for biomedical research, has announced a second tranche investment, effective December 28, 2017, by a wholly-owned subsidiary of OneBlood, Inc., a not-for-profit blood center based in Florida.

  • HemaCare Corp.: Leads amongst peers with strong fundamentals
    Capital Cube5 months ago

    HemaCare Corp.: Leads amongst peers with strong fundamentals

    Categories: Yahoo FinanceHemaCare Corp. relative valuation is OVERVALUED and it has a fundamental analysis score of 61. Our analysis is based on comparing HemaCare Corp. with the following peers – Hooper Holmes, Inc., InfuSystem Holdings, Inc., Tivity Health, Inc., Premier Inc. Class A and CorVel Corporation (HPHW-US, INFU-US, TVTY-US, PINC-US and CRVL-US). HemaCare Corp. has shown good ... Read more (Read more...)

  • Business Wire8 months ago

    HemaCare Plays Mission Critical Role in Global Cellular Therapy Development

    For many years, HemaCare Corporation has been at the epicenter of cellular therapy, immunotherapy, and regenerative medicine research by providing researchers from biotech and pharma companies with mission critical human biological materials from reliable and recallable donors.

  • Business Wire9 months ago

    HemaCare Will Attend Annual CAR-TCR Conference in Boston

    HemaCare Corporation , announced today that it will be attending the annual CAR-TCR conference September 5-8, 2017, in Boston, MA. The conference is focused on the development and commercialization of cell therapy that uses the immune system to fight cancer and other diseases.

  • Business Wire9 months ago

    HemaCare Reports Strong First Half 2017 Results

    HemaCare Corporation today reported financial results for the six months ended June 30, 2017, showing continued robust gains in revenue, gross profit, and net income compared to the same period of 2016.

  • HemaCare Corp.: Strong price momentum but will it sustain?
    Capital Cube9 months ago

    HemaCare Corp.: Strong price momentum but will it sustain?

    Categories: Yahoo FinanceHemaCare Corp. relative valuation is OVERVALUED and it has a fundamental analysis score of 57. Our analysis is based on comparing HemaCare Corp. with the following peers – Hooper Holmes, Inc., InfuSystem Holdings, Inc., Tivity Health, Inc., Premier Inc. Class A and CorVel Corporation (HPHW-US, INFU-US, TVTY-US, PINC-US and CRVL-US). HemaCare Corp. has shown good ... Read more (Read more...)

  • Business Wire10 months ago

    HemaCare Signs Long Term Lease for Facility Relocation and Expansion

    HemaCare Corporation , a leading provider of human blood and immune cells for all stages of cell therapy development announced today that it has signed a long term lease to relocate its operations and corporate headquarters to a larger nearby site in the San Fernando Valley .

  • Business Wire10 months ago

    HemaCare Announces Expansion of Disease State Cells for Bioresearch

    HemaCare Corporation , a leading provider of human blood and immune cells for bioresearch announced today that it has expanded its portfolio of disease state materials in response to increased demand from therapeutic and diagnostic developers.

  • HemaCare Corp.: Strong price momentum but will it sustain?
    Capital Cube11 months ago

    HemaCare Corp.: Strong price momentum but will it sustain?

    Categories: Yahoo FinanceHemaCare Corp. relative valuation is OVERVALUED and it has a fundamental analysis score of 58. Our analysis is based on comparing HemaCare Corp. with the following peers – Hooper Holmes, Inc., InfuSystem Holdings, Inc., Tivity Health, Inc., Premier Inc. Class A and CorVel Corporation (HPHW-US, INFU-US, TVTY-US, PINC-US and CRVL-US). HemaCare Corp. has shown overwhelming ... Read more (Read more...)

  • Business Wire11 months ago

    HemaCare Will Attend the International Society of Stem Cell Research in Boston

    HemaCare Corporation , a leader in cell and tissue collection, processing and cell therapy solutions, will be exhibiting at the annual meeting of the International Society of Stem Cell Research June 14-17 in Boston, MA.